Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database

Risankizumab is a selective, humanized immunoglobulin G1 (IgG1) monoclonal anti-body directed against interleukin (IL)-23 protein. The therapeutic indication of risankizumab is moderate-to-severe plaque psoriasis and psoriatic arthritis. The safety profile of risankizumab is currently defined by dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Calapai, Fabrizio, Ammendolia, Ilaria, Cardia, Luigi, Currò, Mariaconcetta, Calapai, Gioacchino, Esposito, Emanuela, Mannucci, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386550/
https://www.ncbi.nlm.nih.gov/pubmed/37514118
http://dx.doi.org/10.3390/pharmaceutics15071933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386550/
https://www.ncbi.nlm.nih.gov/pubmed/37514118
http://dx.doi.org/10.3390/pharmaceutics15071933

Ejemplares similares